Bispecific antibodies (BsAbs) are antibodies with two binding sites, directed against two different antigens or two different epitopes on the same antigen. BsAbs are clinically superior to monoclonal antibodies (MoAbs) and have a wide range of applications in tumor immunotherapy as well as in the treatment of other diseases such as hemophilia A, diabetes, Alzheimer's disease and ophthalmological diseases. Currently, there are nine bispecific antibodies approved worldwide, more than 180 BsAbs are in preclinical development, and over 50 BsAbs have been investigated in clinical trials.
How Do Bispecific Antibodies Work?
Since BsAbs have two binding sites for different antigens or recognize two different epitopes of an antigen simultaneously, their functional pathways are quite flexible. There are four main mechanisms of action of bispecific antibodies.
- ▶ Recruiting and activating of immune cells to exert their killing effect
- ▶ Blocking of dual signaling pathways
- ▶ Blocking of immune checkpoints
- ▶ Forcing association of protein complexes
Recruiting And Activating Of Immune Cells
An important mechanism of action of bispecific antibodies is to activate immune cells. Bispecific antibodies have two antigen-binding arms, one of which binds to the target antigen and the other to a labeled antigen on the effector cell (T cells and NK cells are commonly used), which activates the effector cell and allows it to target and kill tumor cells. CD3 is currently a popular immune cell surface target for bispecific antibody development, with a greater ability to activate and recruit T cells.
The design of this bispecific antibody focuses on selecting a reasonable range of antibody affinities to inhibit Fc-mediated effector functions as much as possible while having stronger specificity for tumor targets. The marketed blinatumomab (targeting CD3×CD19) removes the Fc structure and reduces the risk of T cell overactivation. Both antibodies use single-chain antibody fragments that do not have an intact IgG structure, reducing CD3 affinity. The CD19 target with high tumor specificity was also selected, with relatively good safety.
Mechanism of blinatumomab
Blocking Of Dual Signaling Pathways
The growth of tumor cells can be simulated or modulated by receptor tyrosine kinase (RTKs), including members of the Her family or insulin-like growth factor (IGF). RTKs are are therefore important targets for tumor therapy. Single-target monoclonal antibodies against RTKs have been widely used in tumor therapy. However, tumor cells can undergo immune escape by switching signaling pathways or by activating intracellular signals through homo- or heterodimerization between HER family members themselves or different members. Therefore, the use of bispecific antibody drugs to interfere/block two (or more) RTK signaling pathways or their ligand simultaneously can reduce tumor cell escape and improve therapeutic efficacy.
Blocking Of Immune Checkpoints
As the development of immunotherapy advances, monoclonal drugs targeting immune checkpoints such as PD-1, PD-L1, and CTLA-4 have become an important tool for oncology treatment, but the clinical efficacy of immune checkpoint monoclonal drugs is still limited and the response rate of patients is still low. Combination therapies of immune checkpoint monoclonal antibodies have demonstrated stronger therapeutic effects than monotherapy in several clinical trials. Therefore, bispecific antibody drugs targeting 2 immune cell surface antigens based on the synergistic effect generated by combination drugs have become a hot research topic.
Forcing Association Of Protein Complexes
The two antigenic arms of a bispecific antibody can bind different antigens. It is possible to make bispecific antibodies that bind two specific protein molecules to form a functional complex that can function in place of the missing functional protein.
For example, Emicizumab (Hemlibra®), a recombinant, humanized, bispecific monoclonal antibody, restores the function of missing activated factor VIII (FVIII) by bridging FIXa and FX to facilitate effective haemostasis in patients with haemophilia A.
Mechanisms of actions of Emicizumab
Clinical Advantages Of Bispecific Antibodies
BsAb has an additional specific antigen-binding site compared to conventional antibodies and has demonstrated the following therapeutic advantages.
- 1) Mediating immune cells to cancer cells to exert a killing effect.
- 2) Dual targeting immune checkpoints, which perform unique or overlapping functions, effectively prevent drug resistance.
- 3) Enhanced specificity, targetability and reduced off-target toxicity. The two antigen-binding arms of the bispecific antibody can bind two antigens on the surface of cancer cells, effectively enhancing the binding specificity and targeting of the antibody to cancer cells and reducing off-target side effects.
- 4) Effectively reduce the cost of treatment. Compared with traditional antibodies, BiTE, for example, has a strong competitive edge in terms of tissue penetration rate, tumor cell killing efficiency, off-target rate and clinical indications, with significant clinical advantages. Especially in terms of dose, since the therapeutic effect of BiTE can reach 100-1000 times that of conventional antibodies, the dose can be as low as 1/2000 of the original dose, which significantly reduces the cost of drug treatment. Compared to combination therapies, the cost of bispecific antibodies is also much lower than the cost of two single-drug combinations.
Global Approved Bispecific Antibodies
Currently, there are nine bispecific antibodies approved worldwide, among them, six bispecific antibodies approved by FDA, including blinatumomab, emicizumab, amivantamab, tebentafusp-tebn and faricimab-svoa, and mosunetuzumab (Table 1).
|Bispecific Antibody Drug Approvals|
|Drug Name||Trade Name||Company||Targets||First Approved Date (Country)||Indications|
|Catumaxomab||Removab||Trion Pharma||CD20/EpCAM||2009 (withdrawn In 2017 )||Malignant ascites|
|Blinatumomab||Blincyto||Amgen||CD3/CD19||Dec 2014 (USA)||Relapsed or refractory precursor B-cell acute lymphoblastic leukemia(ALL)|
|Emicizumab||Hemlibra||Roche||FIXa/FX||Nov 2017 (USA)||Bleeding due to hemophilia A|
|Amivantamab-vmjw||Rybrevant||Janssen||EGFR/cMet||May 2021 (USA)||Non-small cell lung cancer|
|Tebentafusp-tebn||Kimmtrak||Immunocore||GP100/CD3||Jan 2022 (USA)||unresectable or metastatic uveal melanoma|
|Faricimab-svoa||Vabysmo||Genentech||Ang-2/VEGF-A||Jan 2022 (USA)||Wet AMD and DME|
|Cadonilimab||开坦尼®||Akeso, Inc.||PD-1/CTLA-4||Jun 2022 (China)||cervical cancer|
|Mosunetuzumab||Lunsumio||Roche||CD20/CD3||Jun 2022 (EU)||relapsed or refractory (R/R) follicular lymphoma (FL)|
|Teclistamab||Tecvayli||Janssen||BCMA/CD3||Aug 2022 (EU)||relapsed and refractory multiple myeloma|
|Ozoralizumab||Nanozora||Taisho Pharmaceutical||TNFα /TNFα||Sep 2022 (Japan)||inflammatory diseases|
Table 1. Approved Bispecific Antibodies by FDA & EMA
- ▶ In 2014, Amgen's blinatumomab (Blincyto) was approved by the FDA to treat relapsed or refractory precursor B-cell acute lymphoblastic leukemia(ALL) with CD3/CD19 dual targets. Later in 2015, it was approved by EMA.
- ▶ Then in 2017, Roche's emicizumab (Hemlibra) was approved to treat bleeding due to hemophilia A, acting on factor FIXa/FX through the formation of a protein complex. Later in 2018, it was approved by EMA.
- ▶ Later on May 21, 2021, the FDA approved amivantamab-vmjw (Rybrevant) for adult patients with non-small cell lung cancer, targeting the epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET) pathways. And, Rybrevant received a conditional marketing authorization valid throughout the EU on 09 December 2021.
- ▶ On January 25, 2022, the FDA approved tebentafusp-tebn (Kimmtrak, Immunocore Limited), a bispecific gp100 peptide-HLA-directed CD3 T cell engager, for HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.
- ▶ On January 28, 2022, Vabysmo (faricimab-svoa), a vascular endothelial growth factor (VEGF) inhibitor and angiopoietin-2 (Ang-2) inhibitor, was approved for treatment wet, or neovascular, age-related macular degeneration (AMD) and diabetic macular edema (DME).
- ▶ The PD-1/CTLA-4 bispecific antibody 开坦尼® (Cadonilimab injection, AK104) has received marketing approval from the National Medical Products Administration (NMPA) of China, for the treatment of relapsed or metastatic cervical cancer (R/M CC) patients who progressed on or after platinum-based chemotherapy.
- ▶ On June 8, 2022, Roche announced that the European Commission has granted conditional marketing authorization for the CD20xCD3 T-cell binding bispecific antibody Lunsumio (mosunetuzumab) for the treatment of patients with relapsed or refractory (R) disease who have received at least two prior systemic therapies. /R) in adult patients with follicular lymphoma (FL).
- ▶ On August 24, 2022, The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the European Commission (EC) has granted conditional marketing authorisation (CMA) of TECVAYLI® (teclistamab) as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma (RRMM). On October 25, 2022, the FDA granted accelerated approval to Tecvayli.
- ▶ Ozoralizumab (trade name Nanozora) is a humanized monoclonal antibody designed for the treatment of inflammatory diseases. In 2022, ozoralizumab was approved in Japan for the treatment of rheumatoid arthritis.
- ▶ By the way, Catumaxomab was approved in Europe on 20 April 2009. But in 2013, catumaxomab was voluntarily withdrawn from the US market and in 2017 in the EU market for commercial reasons.
The majority of the late-stage clinical development pipeline for bispecific antibodies are bispecific T-cell bridging agents that act to redirect and activate CD3-expressing cytotoxic T cells to target and kill tumor cells expressing specific antigens.
In hematological cancers, the main targets are CD20 and B-cell maturation antigen (BCMA). In solid tumors, the main targets are CTLA4, PD-1/PD-L1, LAG3, EGFR, and HER2/HER3. See the table below for some of the bispecific antibodies that have reached the Phase 3 clinical stage.
Selected oncology bispecific antibodies in phase 3 clinical development (data source: reference )
Early Stage Pipelines
In early clinical development, several bispecific antibodies are targeting existing or innovative targets. In the treatment of hematologic cancers, bispecific antibodies in or planned for registration clinical trials include Regeneron and AbbVie's BCMAxCD3 bispecific antibody, Janssen's GPRC5DxCD3 bispecific antibody talquetamab, MacroGenics' CD123xCD3 bispecific antibody flotetuzumab for acute myeloid leukemia, and Affimed's CD30xCD16A bispecific antibody AFM13 for the treatment of peripheral T-cell lymphoma, among others.
In solid tumors, multiple potential registrational Phase 1/2 clinical trials are underway. Please see the table below for information on some of the therapies in development.
Selected bispecific antibody therapies in early clinical development (data source: reference )
The global market for bispecific antibodies in oncology is expected to expand rapidly, potentially reaching $3.7 billion in sales by 2027. In hematologic cancers, bispecific antibody therapies targeting CD20xCD3 are expected to bring important new treatment options beyond CAR-T cell therapies and established targeted therapies for patients with B-cell non-Hodgkin's lymphoma and diffuse large B-cell lymphoma. In solid tumors, zanidatamab targeting different HER2 epitopes may benefit a large number of patients with HER2-positive gastroesophageal adenocarcinoma.
Beyond the treatment of tumors, bispecific antibody therapies are an important therapeutic modality for the treatment of inflammatory diseases as well as other disease types. They also have multiple other modes of action such as helping macromolecules cross the blood-brain barrier and acting as cofactors to activate signaling cascade pathways. We expect that this innovative therapeutic modality will benefit many more patients in the future.
Biopharma PEG, as a leading PEG supplier, offers high-quality PEG derivatives and raw materials for your drug research and development. These compounds feature great aqueous solubility, a wide range of polymer length/weight, and a broad selection of all the popular functional groups. Please visit our product page for all our in-stock PEG reagents.
 Esfandiari et al., (2022). Bispecific antibodies in oncology. Nature Reviews Drug Discovery, https://doi.org/10.1038/d41573-022-00040-2
 Ma J, Mo Y, Tang M, Shen J, Qi Y, Zhao W, Huang Y, Xu Y, Qian C. Bispecific Antibodies: From Research to Clinical Application. Front Immunol. 2021 May 5;12:626616. doi: 10.3389/fimmu.2021.626616. PMID: 34025638; PMCID: PMC8131538.
Bispecific Antibody Drug Conjugates (ADCs): Emerging Trends
Novel Drug Conjugates – Peptide-Drug Conjugate (PDC) VS Immune Stimulating Antibody Conjugate (ISAC)
Anti-Cancer Peptide Drug Conjugates (PDCs): An Overview
Patterns of Antibody Therapy For Breast Cancer